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ABCB1 polymorphism predicts escitalopram dose
needed for remission in major depression
AB Singh1,2, CA Bousman2,3,4,5, CH Ng2, K Byron6 and M Berk1,2,5,7
The ATP-binding cassette family of transporter proteins, subfamily B (MDR/TAP), member 1 (ABCB1) (P-glycoprotein)
transporter is a key component of the blood–brain barrier. Many antidepressants are subject to ABCB1 efflux. Functional
polymorphisms of ABCB1 may influence central nervous system bioavailability of antidepressants subject to efflux. Single-
nucleotide polymorphisms (SNPs) at rs1045642 (C3435T) of ABCB1 have been associated with efflux pump efficiency. This may
explain part of the interindividual variation in antidepressant dose needed to remit. Individuals (N¼ 113) with DSM-IV (Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition) major depressive disorder (MDD) were treated with escitalopram
(ESC) or venlafaxine (VEN) over 8 weeks. The17-item Hamilton Depression Rating Scale was assessed serially, blind to genotype.
SNP rs1045642 of ABCB1 along with two SNPs previously reported to be in linkage disequilibrium with it (rs2032582 and
rs1128503) were genotyped. Demographic features, clinical features, P450 metabolizer status and 5-HTTLPR (serotonin-
transporter-linked promoter region) genotype were controlled for. Carriers of rs1045642 TT needed on average 11 mg of ESC to
remit, whereas TC and CC carriers required 24 and 19 mg, respectively (P¼ 0.0001). This equates to a 2.0- (95% confidence
interval¼ 1.5–3.4; Po0.001) fold greater ESC dose needed to remit for C carriers compared with TT carriers at rs1045642. Of
VEN-treated subjects carrying TT genotype at rs1045642, 73.3% remitted compared with 12.5% for CC genotype (odds
ratio¼ 6.69; 95% confidence interval¼ 1.72–25.9, P¼ 0.006). These data suggest that antidepressant dose needed to remit can
be predicted by an ABCB1 SNP. This has the potential clinical translation implications for dose selection and remission
from MDD.
Translational Psychiatry (2012) 2, e198; doi:10.1038/tp.2012.115; published online 27 November 2012
Introduction
ATP-binding cassette family of transporter proteins, subfamily
B (MDR/TAP), member 1 (ABCB1) was discovered during the
study of chemotherapeutic resistance in hamster cancer cells.
The involved permeability glycoprotein was then named the
P-glycoprotein.1 Nearly a decade later, the human coding
gene was identified on chromosome 7q21.12 and called the
multidrug resistance 1 (MDR1) gene.2,3 It is now known to be a
member of a larger ABCB1, which is involved in multidrug
resistance.4 ABCB1 has been recently shown to be evenly
expressed and functionally protective across the entire human
brain.5
As with many other genes, the functions of ABCB1 have
been elucidated from the study of abcb1 knockout mice. Such
studies demonstrate much greater entry of tracer agent into
the cerebrospinal fluid (CSF).6,7 ABCB1 is also expressed in
various other tissues, such as the liver, kidney and intestine,
but has greatest expression at the blood–brain barrier (BBB).4
In abcb1 knockout mice, there is an 87-fold greater tracer
entry through the BBB and o4-fold greater entry at other
tissue sites.8 It appears that ABCB1 has a key role in CNS
bioavailability of several psychotropics.9 For example,
blockage of ABCB1 by verapamil or cyclosporin A enhances
the transport of impiramine across the BBB.10
The importance of ABCB1 in drug bioavailability was
emphasized by using human duodenal cells that showed the
TT polymorphism of the rs1045642 single-nucleotide poly-
morphism (SNP) reduced ABCB1 efflux.11 This is a synon-
ymous SNP producing a codon that does not change the
expressed amino acid (isoleucine). These data do not easily
explain the potential mechanism by which rs1045642 poly-
morphism may affect ABCB1 bioactivity. It has been
suggested that rs1045642 is in linkage disequilibrium (LD)
with the nonsynonymous SNP rs2032582 (Ala893Thr/Ser) on
ABCB1, raising the possibility that the Thr/Ser variation could
be affecting protein function, with rs1045642 merely acting as
a ‘tag-SNP’ for it.12–14 However, many other studies suggest
that rs1045642 is not in LDwith rs2032582.15–23 Furthermore,
a study of CSF/serum ratios of the anticonvulsant phenobar-
bitol in 60 patients found that rs1045642 and not rs2032582
influenced the CSF/serum ratio, with TT carriers at rs1045642
having a significantly higher ratio consistent with reduced
ABCB1 efflux.24 Lastly, a study of 332 epileptic patients
demonstrated that carriers of the TT allele at rs1045642 were
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more responsive to anticonvulsants, with no association found
with rs2032582 polymorphism.15 This association has been
replicated in a subgroup of 160 epileptic patients.16 Taken
together, these data suggest that the synonymous rs1045642
SNP has functional effects on ABCB1. In a study utilizing
cultured human HeLa cell lines, TT genotype at rs1045642
resulted in use of the rarer isoleucine codon (ATT rarer than
ATC), altering ABCB1 conformational folding and efflux
functioning.25 These data suggest that rs1045642 can affect
ABCB1 functionality without changes in amino-acid seq-
uence, and provides a mechanism explanation for the asso-
ciation of rs1045642 polymorphisms to ABCB1 functioning.
Studies with abcb1 knockout mice have demonstrated that
citalopram, escitalopram (ESC), paroxetine, sertraline, ven-
lafaxine (VEN), desvenlafaxine, reboxetine, doxepin, amitrip-
tyline and trimipramine are substrates for ABCB1; however,
fluoxetine, mirtazapine, bupropion and melperone are
not.26–31 Polymorphisms of the ABCB1 gene are reported to
predict selective serotonin re-uptake inhibitor tolerability.32
However, no association with nortriptyline-induced postural
hypotension and ABCB1 polymorphisms were shown.33
Three studies have found an association between ABCB1
polymorphisms and improvement on antidepressants subject
to ABCB1 efflux.22,30,34 Relapse after response (Z50%
reduction in 17-item Hamilton Depression Rating Scale
(HDRS)) but not remission (HDRS r7) is common, making
remission the aim in clinical care.35 The aims of this study
were to investigate for associations between ABCB1 poly-
morphisms and antidepressant dose needed to remit in MDD.
The primary hypothesis of this studywas that polymorphism of
rs1045642 would predict dose needed to remit from major
depression, with C carriers needing significantly higher doses
for remission. The secondary hypothesis was that polymorph-
ism of rs1045642 would predict probability of remission, with
TT genotype significantly more likely to remit. Finally, the
influence of two ABCB1 SNPs previously described to be in
LD with rs1045642 (rs2032582 and rs1128503) were also
examined to determine if they were in LD with rs1045642 in
this study population.
Methods
Subjects and ratings. Subjects where either of Caucasian
(European, recruited from two sites in Australia) or Asian
(Han Chinese, recruited from a third site in Singapore)
background. Patients 18 years and over with a principal
diagnosis of MDD (Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition criteria, assessed by
semistructured clinical interview) were studied. An HDRS
score ofZ18 was required to exclude milder cases of MDD,
which may be less medication responsive.36 Patients who
had treatment refractory depression (Z3 failed medication
trials) were excluded as more aggressive treatments were
clinically appropriate. Patients were studied prospectively for
8 weeks with HDRS ratings as the primary outcome. Clinical
global impression scales for improvement and severity were
used as a secondary outcome measures to guide clinical
dose adjustment. Ratings were blinded to genotype. Before
commencement, there was a drug washout period (five half-
lives of the previous agent) for subjects already receiving an
antidepressant. During the first week, all patients received a
standard dose of either ESC 10mg or VEN 75mg per day.
Drug selection was based on patient’s preference of side-
effect profile. At weeks 1, 4 and 8 of treatment, doses were
adjusted on a clinical basis, with the dose escalated if there
was no improvement on the clinical global impression scale,
or the dose reduced if problematic side effects emerged
(elevation of the UKU side effects scale37 with patient
intolerance of the reported side effect). No other psychotropic
medications were given and psychotherapy was not com-
menced during the study period. Genotyping of CYP2D6 and
CYP2C19 polymorphisms was conducted to control for
metabolized status as a potential confounder for dose
needed to remit. In addition, 5-HTTLPR (serotonin-transpor-
ter-linked promoter region) genotype was assessed as a
potential antidepressant efficacy confounder.38 Three
ABCB1 SNPs (rs1045642, rs2032582 and rs1128503) were
assayed. The study was approved by an independent
research ethics committee (Study 138; The Melbourne Clinic,
Richmond, VIC, Australia).
SNP analysis. DNA was extracted from each sample
using QIAamp DNA Mini Kit (Qiagen, Melbourne, VIC,
Australia) from venous blood or buccal brush samples.
Genotype of candidate SNPs was determined by the poly-
merase chain reaction followed by single primer extension
and analysis on a Sequenom Matrix-assisted laser deso-
rption/ionization time-of-flight mass spectrometry (Sequenom,
San Diego, CA, USA) 384-well genetic analysis system. For
the large duplications and deletions of the CYP2D6 gene, as
well as determining the 5-HTTLPR genotype, standard long-
range polymerase chain reaction was used.
Statistical analysis. Data were analyzed using SPSS
(version 19, IBM, Armonk, NY, USA). Intention-to-treat analysis
was applied. Repeated-measures analysis of variance was
used to determine changes in HDRS scores and anti-
depressant dose over time by each of three genotypes of
the ABCB1 SNPs studied. Genotype-wise differences were
examined using a post hoc pairwise analysis with a
Bonferroni correction (P¼ 0.017). Logistic regression was
used to estimate the odds ratio and 95% confidence intervals
for each ABCB1 polymorphism on symptom remission. To
examine differences in dose among responders and remit-
ters by ABCB1 genotype, w2 analysis was performed. The
CubeX program39 was applied to detect departures from
Hardy–Weinberg equilibrium and estimate pairwise LD
measures r2 and D0. SNPs with Hardy–Weinberg equilibrium
40.01 were considered to be in equilibrium. LD was assumed if
a pair of SNPs had r2 and D 0 values 40.80.
Results
Of 113 subjects screened, 107were enrolled in the study. Two
patients withdrew consent early for undetermined reasons.
Seven patients disengaged before either week 4 or 8,
preventing remission assessment. Thus, 98 subjects of the
107 enrolled had sufficient data to analyze response,
remission, dose and genotype. In all, 57 subjects were
prescribed ESC and 41 VEN.
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Demographic and clinical variables (including baseline
HDRS and duration of episode), CYP2D6 and CYP2C19
metabolizer status and 5-HTTLPR genotype among the
three ABCB1 loci studied is displayed in Table 1. Among
subjects treated with ESC, there was a significant difference
in the mean duration of depressive episode between
the three possible rs2032582 genotypes (Table 1). There
was also a significant difference between the three
possible rs1128503 genotypes and the proportion of female
patients in each group (Table 1). However, there were no
significant differences among these characteristics
between the three rs1045642 genotype groups (Table 1).
Importantly, significant ethnic differences by ABCB1 poly-
morphisms were not observed. Thus, we did not perform
analysis stratified by ethnicity. In addition, all three ABCB1
SNPs were in Hardy–Weinberg equilibrium and pairwise LD
analysis showed that all three SNPs were at independent loci
(r2 and/or D0 o0.80; Table 2). Thus, haplotype analysis was
not performed.
There was a Bonferroni-corrected significant finding for the
TT genotype of rs1045642 to better odds of remitting (odds
ratio¼ 6.69; 95% confidence interval¼ 1.72–25.9, P¼ 0.006)
among subjects treated with VEN but not ESC (Table 3 and
Figure 1a). No association between polymorphisms of
rs2032582 or rs1128503 to antidepressant remission rate
was observed.
There was a Bonferroni-corrected significant association of
the TT genotype to a lower average dose of ESC needed to
remit for all three ABCB1 SNPs examined (Table 4). Carriers
of rs1045642 TT needed on average 11mg of ESC to remit,
whereas TC and CC carriers required 24 and 19mg,
respectively (P¼ 0.0001). This equates to a 2.0- (95%
confidence interval¼ 1.5–3.4; Po0.001) fold greater ESC
dose needed to remit for C carriers compared with TT carriers
at rs1045642 (Figure 1b). At rs2032582, TT carriers needed
on average 10mg to remit and TC carriers 22mg (P¼ 0.008).
At rs1128503, TT carriers needed on average 11mg to remit
and TC carriers 23mg (P¼ 0.0002).
Discussion
These data demonstrate that the ABCB1 rs1045642 poly-
morphism predicts ESC dose needed for remission controlled
for various demographic, clinical and genetic confounders. C
carriers at rs1045642 needed a 2.0-fold higher dose of ESC to
remit. As 69% of all subjects were C carries at rs1045642, this
polymorphism represents a substantial proportion of subjects
with translational implications if replicated. As rs1045642 was
not in LDwith rs2032582 or rs1128503, it does not appear that
rs1045642 is acting as a ‘tag-SNP’ to these ABCB1 SNPs, but
has a direct association to VEN remission rate and ESC dose
needed to remit. Similar findings for ESC dose needed to remit
were made for the other two ABCB1 SNPs studied, but with
the potential confounder of a significantly different mean
duration of depressive episode among the rs2032582
genotypes, and a significant difference in the gender distribu-
tion among the rs1128503 genotypes. There were no such
Table 3 Symptom remission by antidepressant and ABCB1 genotype
dbSNP ID N Symptom remission (HDRSr7) according to genotype ORa 95% CI P-value
Escitalopram
rs1045642 (C3435T) 57 CC: 8/13 (61.5%) CT: 16/29 (55.2%) TT: 11/15 (73.3%) 1.25 0.52–3.02 0.614
rs2032582 (G2677T/A) 57 CC: 6/12 (50.0%) CT: 22/35 (61.0%) TT: 8/10 (80.0%) 1.84 0.44–4.63 0.192
rs1128503 (C1236T) 57 CC: 8/14 (57.1%) CT: 18/30 (60.0%) TT: 9/13 (69.2%) 1.16 0.46–2.92 0.748
Venlafaxine
rs1045642 (C3435T) 41 CC: 1/8 (12.5%) CT: 11/18 (61.1%) TT: 11/15 (73.3%) 6.69 1.72–25.9 0.006b
rs2032582 (G2677T/A) 41 CC: 4/9 (44.4%) CT: 8/20 (40.0%) TT: 10/12 (83.3%) 4.04 1.27–12.8 0.018
rs1128503 (C1236T) 41 CC: 4/9 (44.4%) CT: 6/14 (42.9%) TT: 12/18 (66.6%) 1.92 0.77–4.80 0.165
Abbreviations: ABCB1, ATP-binding cassette family of transporter proteins, subfamily B (MDR/TAP), member 1; CI, confidence interval; HDRS, 17-item Hamilton
Depression Rating Scale; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAdjusted for ethnicity and education. bSignificant after Bonferroni correction (Po0.017 needed).
Table 2 Linkage disequilibrium for ABCB1 SNPs
Position dbSNP LD 1 2 3
87138645 rs1045642 (C3435T) 1 — 0.62 0.39
87160618 rs2032582 (G2677T/A) 2 0.31 — 0.83 D 0
87179601 rs1128503 (C1236T) 3 0.15 0.57 —
r2
Abbreviations: ABCB1, ATP-binding cassette family of transporter proteins,
subfamily B (MDR/TAP), member 1; LD, linkage disequilibrium; SNP, single-
nucleotide polymorphism.
Figure 1 Symptom remission and dose needed for remission by ABCB1
genotype. (a) A larger proportion of TT genotype carriers achieve symptom
remission with venlafaxine over 8 weeks (*P¼ 0.006). (b) TT genotype carriers
required a significantly lower average dose of escitalopram compared with C allele
carriers to remit (**P¼ 0.0001). Bars represent standard error of the mean.
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potential confounders of baseline features among the three
rs1045642 genotypes analyzed for associations to antide-
pressant dose needed to remit.
The association of rs1045642 polymorphism to dose
needed to remit on ESC was not seen for subjects treated
with VEN. This may be explained by the longer process of
dose titration needed for VEN compared with ESC. During the
8 weeks of the study, it was easier to escalate the dose of ESC
to its maximum of 30mg than to escalate the dose of VEN to
its maximum of 450mg due to the much smaller clinical dose
range of ESC. In fact, during the 8 weeks of this study, the
highest dose of VEN reached was 300mg. Some subjects
treated with VEN may have been inadvertently under-dosed,
with subsequent inadequate CNS bioavailability and reduced
remission rates. This may explain why the only significant
finding for genotype to remission rate was for subjects treated
with VEN, with those carrying the TT allele at rs1045642
showing a significantly greater remission rate. This lower
ABCB1 efflux group may have greater CNS bioavailability of
VEN at the lower doses reached during this 8-week study, and
hence a significantly greater remission rate. Conversely, as
ESC could be escalated to an adequate dose faster, C carriers
could have their dose escalated to enable adequate CNS
bioavailability with no significant remission rate differences
between groups discernible. These findings appear to support
the hypothesis that C carriers at the rs1045642 may have
higher ABCB1 efflux and reduced CNS bioavailability of the
antidepressants studied. Furthermore, this suggests that C
carriers at rs1045642 treated with VEN could become
remitters if their medication dose was escalated further.
Longer follow-up could have helped answer this question by
enabling greater doses of VEN to be attained.
A strength of this study was controlling forP450metabolizer
status and 5-HTTLPR genotype, both of whichmay impact the
efficacy of antidepressants.38,40 As serum levels of ESC and
VEN will influence CNS bioavailability, not controlling for
antidepressant serum levels was a limitation. Trough serum
antidepressant level covariance analysis to the ABCB1 SNPs
examined could be explored in future studies to help control for
this factor. This study analyzed P450 metabolizer status in an
attempt to address this issue. Having subject CSF samples
would enable a serum to CSF ratio to be determined and
correlated to ABCB1 genotype. Such studies are difficult to
establish, but they would provide robust evidence of the role of
ABCB1 polymorphisms to antidepressant CNS bioavailability.
This study would have also benefited from a greater sample
size to improve power, but by the same token clinically
translatable effect sizes should emerge in moderate samples.
A further limitation of this study was not controlling for early life
and recent stressors as such seem to influence antidepressant
responsiveness putatively by epigenetic mechanisms.41,42
Previous positive studies demonstrating a significant
association between ABCB1 polymorphisms and HDRS
score reduction, response and remission22,30,32 reflect results
akin to the VEN group finding in this study. Namely, that
certain ABCB1 genotypes needed a higher dose to remit but
were inadequately dosed during the study period, and thus
had a significantly lower remission rate than the TT carriers at
rs1045642. This study has potential clinical translation and
compliments the recent understanding of how synonymous
SNPs can have functional outcomes through conformational
folding of ABCB1 due to rs1045642 polymorphism.
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Table 4 Average antidepressant dose (mg) among remitters by ABCB1
genotypea
SNP N Venlafaxine N Escitalopram
rs1045642 (C3435T)
CC 1 150 (0) 8 19 (8)
CT 11 150 (70) 16 24 (7)
TT 11 120 (72) 11 11 (3)
P-value 0.639 0.0001b (TToCT and CC)
rs2032582 (G2677T/A)
CC 4 131 (38) 6 20 (6)
CT 8 150 (95) 21 22 (8)
TT 10 130 (68) 7 10 (0)
P-value 0.851 0.003b (TToCT and CC)
rs1128503 (C1236T)
CC 4 131 (38) 8 18 (7)
CT 6 165 (98) 18 23 (8)
TT 12 125 (67) 9 11 (3)
P-value 0.577 0.001b (TToCT and CC)
Abbreviations: ABCB1, ATP-binding cassette family of transporter proteins,
subfamily B (MDR/TAP), member 1; HDRS, 17-item Hamilton Depression
Rating Scale; SNP, single-nucleotide polymorphism.
aRemission defined as an HDRS score r7. bSignificant after Bonferroni
correction (Po0.017 needed).
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